Immuneering (NASDAQ:IMRX) Given Buy Rating at Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a research report issued on Monday,Benzinga reports. They presently have a $13.00 target price on the stock.

Several other analysts have also commented on IMRX. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of Immuneering in a research report on Friday.

Immuneering Stock Up 9.1 %

NASDAQ IMRX opened at $1.80 on Monday. The business’s fifty day simple moving average is $1.79 and its 200-day simple moving average is $2.00. The firm has a market cap of $55.89 million, a PE ratio of -0.91 and a beta of -0.32. Immuneering has a 52 week low of $1.00 and a 52 week high of $3.83.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16). Research analysts expect that Immuneering will post -1.86 EPS for the current year.

Hedge Funds Weigh In On Immuneering

Several large investors have recently made changes to their positions in the stock. HighTower Advisors LLC raised its position in Immuneering by 21.4% in the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares during the period. Corsair Capital Management L.P. acquired a new stake in shares of Immuneering in the third quarter valued at $25,000. Southport Management L.L.C. raised its holdings in shares of Immuneering by 4.9% in the 4th quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock valued at $473,000 after buying an additional 10,000 shares during the period. Two Sigma Investments LP lifted its stake in Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after acquiring an additional 10,126 shares in the last quarter. Finally, Tang Capital Management LLC purchased a new position in Immuneering during the 4th quarter valued at about $27,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.